The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets

Pancreas. 1995 Aug;11(2):196-200. doi: 10.1097/00006676-199508000-00014.

Abstract

Glucagon-like peptide-I (GLP-I) is a potent incretin hormone that is now considered as a new therapeutic tool in the treatment of diabetes mellitus. In this study we characterized the effects of GLP-I on peptide hormone release from isolated human pancreatic islets. GLP-I stimulated insulin release in the presence of 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 166%; 10 mM glucose + 10 nM GLP-I, 222%) but had only a weak insulinotropic effect (128%) at 2.8 mM glucose. Glucagon release was inhibited by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 72%) and by 10 nM GLP-I at 2.8 mM glucose (67%). Somatostatin secretion was increased by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 166%). GLP-I stimulated somatostatin release in the presence of 2.8 mM glucose (172%). Pancreatic polypeptide (PP) secretion was enhanced by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 236%). GLP-I induced PP release only in the presence of 2.8 mM glucose (184%).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Culture Techniques
  • Glucagon / metabolism*
  • Glucagon / pharmacology*
  • Glucagon-Like Peptide 1
  • Glucose / pharmacology
  • Humans
  • Insulin / metabolism*
  • Insulin Secretion
  • Islets of Langerhans / drug effects
  • Islets of Langerhans / metabolism*
  • Pancreatic Polypeptide / metabolism*
  • Peptide Fragments / pharmacology*
  • Protein Precursors / pharmacology*
  • Somatostatin / metabolism

Substances

  • Insulin
  • Peptide Fragments
  • Protein Precursors
  • Somatostatin
  • Pancreatic Polypeptide
  • Glucagon-Like Peptide 1
  • Glucagon
  • Glucose